Zhang Qi-Qing, Luo Xin-Xin, Chen Hua, Wang Wei, Xie Yi-Fan, Qiao Hong-Li, Miao Hao-Jun, Feng Zheng-Quan
Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
College of Integrated Traditional Chinese and Western Medicine Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Front Immunol. 2025 Aug 5;16:1614911. doi: 10.3389/fimmu.2025.1614911. eCollection 2025.
This case report presents a rare instance of synchronous multiple primary cancers involving lung adenocarcinoma with bone metastasis, gastric signet-ring cell carcinoma, and rectal cancer. The 64-year-old male patient was treated with a combination of sintilimab, chemotherapy, and targeted therapy. Following a multidisciplinary team consultation, systemic treatment with sintilimab, oxaliplatin, and capecitabine was initiated concurrently while furmonertinib targeted therapy continued. After six cycles, the lung lesions showed significant reduction, while the gastric and intestinal tumors remained stable. The patient transitioned to maintenance therapy and achieved sustained disease control without severe adverse effects. This case highlights the potential of an integrated immunotherapy and chemotherapy approach for treating multiple primary malignancies with distinct pathological origins. report also underscores the need for individualized, biomarker-driven treatment strategies and further research on optimal therapeutic combinations for synchronous multiple primary cancers.
本病例报告展示了一例罕见的同步性多原发性癌症，涉及肺腺癌伴骨转移、胃印戒细胞癌和直肠癌。该64岁男性患者接受了信迪利单抗、化疗和靶向治疗的联合治疗。经过多学科团队会诊后，同时开始使用信迪利单抗、奥沙利铂和卡培他滨进行全身治疗，而伏美替尼靶向治疗继续进行。六个周期后，肺部病变显著缩小，而胃肠道肿瘤保持稳定。患者转为维持治疗并实现了持续的疾病控制，且无严重不良反应。本病例突出了免疫治疗与化疗相结合的方法在治疗具有不同病理起源的多原发性恶性肿瘤方面的潜力。报告还强调了个性化、生物标志物驱动的治疗策略的必要性，以及对同步性多原发性癌症最佳治疗组合的进一步研究。
